Atea Pharmaceuticals Inc
Atea Pharmaceuticals Inc (AVIR) Historical Volatility
AVIR's 30 day historical volatility is 55.73%, in the 73rd percentile of readings over the past year. This is a high percentile, meaning Atea Pharmaceuticals Inc shares have swung far more than usual. AVIR's 30 day implied volatility sits at 115.48%, with an IV Rank of 28.97%, leaving IV 59.75 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 17, 2026.
Read more
Tracking AVIR historical volatility helps you see how much Atea Pharmaceuticals Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, AVIR's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor AVIR 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. AVIR's 30 day historical volatility, or AVIR HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing AVIR's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 17, 2026
As of Nov 17, 2026
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →